Document Detail

Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.
MedLine Citation:
PMID:  19865105     Owner:  NLM     Status:  MEDLINE    
The role of uric acid (UA) in human physiology is subject to controversy. Either it is an important radical scavenger, a mostly neutral, waste metabolic product that may cause gout and kidney stones if elevated, or it is involved in the causation of hypertension, vascular and renal diseases. Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis. An important aspect of the safety profile is whether raising the serum UA levels elevates blood pressure. During the 1-year trial, blood pressure and serum UA levels were monitored in 16 patients. Both parameters were recorded throughout the trial that included 69 visits by patients at baseline and during the placebo phase as well as 138 visits while receiving inosine treatment. We have observed that although the serum UA levels increased significantly during the inosine treatment phase of the trial, from 4.2+/-0.8 to 7.1+/-1.7 mg per 100 ml, blood pressure remained unchanged, averaging 123+/-15/78+/-9. Our findings indicate that raising the serum UA levels to upper normal physiological levels for a period of up to 1-year does not influence blood pressure significantly.
S Spitsin; C E Markowitz; V Zimmerman; H Koprowski; D C Hooper
Related Documents :
22521485 - Physiological effects following administration of citrus aurantium for 28days in rats.
16253725 - Association between carotid artery intima-media thickness and cardiovascular risk facto...
14631835 - Influence of hypertension, lipometabolism disorders, obesity and other lifestyles on sp...
17990325 - Biological condition of adult migrants and nonmigrants in wrocław, poland.
7620695 - Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. t...
1491635 - Compartmental syndrome in duchenne muscular dystrophy: early evaluation of an epiphenom...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-10-29
Journal Detail:
Title:  Journal of human hypertension     Volume:  24     ISSN:  1476-5527     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  359-62     Citation Subset:  IM    
Biotechnology Foundation Laboratories, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Blood Pressure / drug effects*,  physiology
Cross-Over Studies
Double-Blind Method
Inosine / administration & dosage,  pharmacology*
Middle Aged
Multiple Sclerosis / blood*,  physiopathology*
Treatment Outcome
Uric Acid / blood*
Grant Support
Reg. No./Substance:
58-63-9/Inosine; 69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mapping of Char10, a novel malaria susceptibility locus on mouse chromosome 9.
Next Document:  Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential...